Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.

Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Bayer has taken steps to address the concerns of its stockholders by pulling together a legal team for its ongoing US glyphosate litigation, and bringing on board Merck’s Vioxx lawyer.

European fund manager Vesalius has closed its third fund with €120m. Its managers believe their strategy of investing in maturing companies has been the key to attracting commitments, including from the European Investment Fund.

AMAG Pharmaceutical’s HSDD drug Vyleesi, has been approved by the FDA. But analysts warn it must build the market in women who may not be aware they have a condition if it is to fare better than Sprout’s Addyi.